KR102904932B1 - 전사 인자 eb 폴리펩티드 수준을 증가시키기 위한 방법 및 물질 - Google Patents
전사 인자 eb 폴리펩티드 수준을 증가시키기 위한 방법 및 물질Info
- Publication number
- KR102904932B1 KR102904932B1 KR1020217022772A KR20217022772A KR102904932B1 KR 102904932 B1 KR102904932 B1 KR 102904932B1 KR 1020217022772 A KR1020217022772 A KR 1020217022772A KR 20217022772 A KR20217022772 A KR 20217022772A KR 102904932 B1 KR102904932 B1 KR 102904932B1
- Authority
- KR
- South Korea
- Prior art keywords
- delete delete
- disease
- alkyl
- compound
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962788049P | 2019-01-03 | 2019-01-03 | |
| US62/788,049 | 2019-01-03 | ||
| US201962879374P | 2019-07-26 | 2019-07-26 | |
| US62/879,374 | 2019-07-26 | ||
| PCT/US2020/012268 WO2020142748A1 (en) | 2019-01-03 | 2020-01-03 | Methods and materials for increasing transcription factor eb polypeptide levels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210111787A KR20210111787A (ko) | 2021-09-13 |
| KR102904932B1 true KR102904932B1 (ko) | 2025-12-26 |
Family
ID=71406977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217022772A Active KR102904932B1 (ko) | 2019-01-03 | 2020-01-03 | 전사 인자 eb 폴리펩티드 수준을 증가시키기 위한 방법 및 물질 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12286442B2 (https=) |
| EP (1) | EP3906033A4 (https=) |
| JP (1) | JP7566753B2 (https=) |
| KR (1) | KR102904932B1 (https=) |
| CN (1) | CN113316453B (https=) |
| AU (1) | AU2020204717B2 (https=) |
| BR (1) | BR112021012950A2 (https=) |
| CA (1) | CA3123902A1 (https=) |
| IL (1) | IL284403A (https=) |
| MX (1) | MX2021008152A (https=) |
| SG (1) | SG11202105685TA (https=) |
| WO (1) | WO2020142748A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023533016A (ja) | 2020-07-11 | 2023-08-01 | ファイザー・インク | 抗ウイルス性ヘテロアリールケトン誘導体 |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| CZ309449B6 (cs) * | 2020-12-24 | 2023-01-25 | Ústav experimentální botaniky AV ČR, v. v. i. | Chinazolinové deriváty jako selektivní inhibitory cyklooxygenázy-1 |
| CN113248518B (zh) * | 2021-06-21 | 2022-03-25 | 山东大学 | 嘧啶哌嗪类衍生物及其制备方法与应用 |
| CN121941701A (zh) * | 2023-07-28 | 2026-04-28 | 特兰埃克斯公司 | 用于治疗溶酶体病症的突变tfeb |
| CN119818678A (zh) * | 2024-12-24 | 2025-04-15 | 广州医科大学附属妇女儿童医疗中心 | Tfeb在制备变应性鼻炎的药物中的应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003057695A1 (en) | 2001-12-21 | 2003-07-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,6 naphthyridines useful as inhibitors of syk kinase |
| WO2010015518A2 (de) | 2008-08-05 | 2010-02-11 | Boehringer Ingelheim Interntional Gmbh | 4-dimethylamino-phenyl-substituierte naphthyridine und ihre verwendung als arzneimittel |
| US20110201608A1 (en) * | 2008-08-05 | 2011-08-18 | Boehringer Ingelheim International Gmbh | Substituted naphthyridines and use thereof as medicines |
| WO2011134971A1 (en) * | 2010-04-29 | 2011-11-03 | Glaxo Group Limited | 7-(1h-pyrazol-4-yl)-1,6-naphthyridine compounds as syk inhibitors |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| WO2002022605A1 (en) * | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| JP2005503425A (ja) | 2001-05-24 | 2005-02-03 | アレックザ モレキュラー デリヴァリー コーポレイション | 所定の吸入ルートによる薬剤エステルの送出 |
| AU2003286711A1 (en) * | 2002-10-25 | 2004-05-13 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
| CL2004000409A1 (es) | 2003-03-03 | 2005-01-07 | Vertex Pharma | Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu |
| US7198926B2 (en) * | 2003-05-08 | 2007-04-03 | E. I. Du Pont De Nemours And Company | Preparation of (E)- and (Z)-2-methyl-2-butenoic acids |
| EP1622615A4 (en) | 2003-05-13 | 2009-02-18 | Smithkline Beecham Corp | INHIBITORS OF THE INTEGRASE OF NAPHTHYRIDINE |
| WO2008157500A1 (en) * | 2007-06-17 | 2008-12-24 | Kalypsys, Inc. | Aminoquinazoline cannabinoid receptor modulators for treatment of disease |
| CA2705303A1 (en) * | 2007-11-07 | 2009-05-14 | Foldrx Pharmaceuticals, Inc. | Modulation of protein trafficking |
| GB201007347D0 (en) | 2010-04-30 | 2010-06-16 | Karus Therapeutics Ltd | Compounds |
| CN104812387A (zh) | 2012-11-20 | 2015-07-29 | 霍夫曼-拉罗奇有限公司 | 取代的1,6-萘啶 |
| CN107205976A (zh) * | 2014-11-19 | 2017-09-26 | 拉什大学医学中心 | 用于治疗溶酶体病症的组合物和方法 |
| WO2018089433A1 (en) | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | PHENYL mTORC INHIBITORS AND USES THEREOF |
| WO2018089499A1 (en) * | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF |
| WO2018089493A1 (en) * | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | PYRROLE mTORC INHIBITORS AND USES THEREOF |
| WO2018191146A1 (en) * | 2017-04-10 | 2018-10-18 | Navitor Pharmaceuticals, Inc. | Heteroaryl rheb inhibitors and uses thereof |
-
2020
- 2020-01-03 BR BR112021012950-2A patent/BR112021012950A2/pt unknown
- 2020-01-03 MX MX2021008152A patent/MX2021008152A/es unknown
- 2020-01-03 EP EP20736104.9A patent/EP3906033A4/en active Pending
- 2020-01-03 WO PCT/US2020/012268 patent/WO2020142748A1/en not_active Ceased
- 2020-01-03 KR KR1020217022772A patent/KR102904932B1/ko active Active
- 2020-01-03 US US17/420,597 patent/US12286442B2/en active Active
- 2020-01-03 JP JP2021538743A patent/JP7566753B2/ja active Active
- 2020-01-03 SG SG11202105685TA patent/SG11202105685TA/en unknown
- 2020-01-03 CN CN202080007921.4A patent/CN113316453B/zh active Active
- 2020-01-03 CA CA3123902A patent/CA3123902A1/en active Pending
- 2020-01-03 AU AU2020204717A patent/AU2020204717B2/en active Active
-
2021
- 2021-06-27 IL IL284403A patent/IL284403A/en unknown
-
2025
- 2025-01-23 US US19/035,805 patent/US20250382309A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003057695A1 (en) | 2001-12-21 | 2003-07-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,6 naphthyridines useful as inhibitors of syk kinase |
| WO2010015518A2 (de) | 2008-08-05 | 2010-02-11 | Boehringer Ingelheim Interntional Gmbh | 4-dimethylamino-phenyl-substituierte naphthyridine und ihre verwendung als arzneimittel |
| US20110201608A1 (en) * | 2008-08-05 | 2011-08-18 | Boehringer Ingelheim International Gmbh | Substituted naphthyridines and use thereof as medicines |
| WO2011134971A1 (en) * | 2010-04-29 | 2011-11-03 | Glaxo Group Limited | 7-(1h-pyrazol-4-yl)-1,6-naphthyridine compounds as syk inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210111787A (ko) | 2021-09-13 |
| BR112021012950A2 (pt) | 2021-09-14 |
| US12286442B2 (en) | 2025-04-29 |
| AU2020204717A1 (en) | 2021-06-10 |
| CA3123902A1 (en) | 2020-07-09 |
| JP2022516631A (ja) | 2022-03-01 |
| SG11202105685TA (en) | 2021-06-29 |
| CN113316453A (zh) | 2021-08-27 |
| US20250382309A1 (en) | 2025-12-18 |
| EP3906033A1 (en) | 2021-11-10 |
| US20220112218A1 (en) | 2022-04-14 |
| AU2020204717B2 (en) | 2025-01-16 |
| IL284403A (en) | 2021-08-31 |
| MX2021008152A (es) | 2021-10-13 |
| EP3906033A4 (en) | 2022-11-09 |
| JP7566753B2 (ja) | 2024-10-15 |
| CN113316453B (zh) | 2025-12-23 |
| WO2020142748A1 (en) | 2020-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102904932B1 (ko) | 전사 인자 eb 폴리펩티드 수준을 증가시키기 위한 방법 및 물질 | |
| TWI458723B (zh) | １，２－雙取代雜環化合物 | |
| EP3464292B1 (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | |
| EP3720858B1 (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | |
| EP2298731A1 (en) | Amide compound | |
| JP6851825B2 (ja) | 非アポトーシス性の制御された細胞死の阻害剤としてのスピロキノキサリン誘導体 | |
| CN110023311B (zh) | 2-取代的氨基-萘并[1,2-d]咪唑-5-酮类化合物或其药学上可接受的盐 | |
| EP2753327A2 (en) | Amido compounds as ror-gamma-tmodulators and uses thereof | |
| JP2013519724A (ja) | Ｎａｄｐｈオキシダーゼ阻害剤としてのピラゾロピペリジン誘導体 | |
| CN114746430A (zh) | 治疗线粒体异常疾病的伐替苯醌的醌-、氢醌-和萘醌-类似物 | |
| EP2521726B1 (fr) | Dérivés de 5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine comme inhibiteurs de kinases camkii pour le traitement de maladies cardiovasculaires | |
| WO2020172565A1 (en) | Methods and materials for increasing or maintaining nicotinamide mononucleotide adenylyl transferase-2 (nmnat2) polypeptide levels | |
| JP2021523934A (ja) | ミトコンドリア脱共役剤として有用なアミノピラジンおよび関連化合物 | |
| CN109748914B (zh) | 吡啶并嘧啶类化合物及其应用 | |
| RU2838857C2 (ru) | Способы и материалы для повышения уровней полипептида фактора транскрипции eb | |
| CA3181351A1 (en) | Nampt modulators | |
| WO2019185033A1 (zh) | 用作fgfr不可逆抑制剂的酰胺基吡唑类化合物 | |
| CN115109040A (zh) | 抗真菌化合物，包含其的药物组合物和制剂，及其应用 | |
| WO2025113519A1 (zh) | 内酰胺环类化合物及其用途 | |
| WO2015090224A1 (zh) | 新型哌啶氨甲酰类化合物、制备方法及其用途 | |
| CN102718757B (zh) | 具有α-葡萄糖苷酶抑制活性的2H-1-苯并吡喃-2-酮类化合物及其药用组合物 | |
| HK40039344A (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | |
| HK40039344B (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | |
| HK40004811A (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | |
| HK40004811B (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| U12 | Designation fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |